Skip to nav Skip to content

Updates on CDC’s New Respiratory Virus Guidance, COVID Antivirals & the Emergence of Clade I Mpox

Facebook Twitter LinkedIn Email

To Download a copy of the presentation click here.
To Download a copy of the Q&A Responses click here.

Dana S. Wollins, DrPH, MGC
Senior Vice President, Strategy
Infectious Diseases Society of America


Clade-1 Mpox: Update & Preparing for Potential Future Spread
Agam Rao, MD, FIDSA
CAPT, U.S. Public Health Service 
Medical Officer 
Poxvirus and Rabies Branch
U.S. Centers for Disease Control and Prevention

CDC’s New Respiratory Infection Guidance
Brendan Jackson, MD, MPH
Commander, U.S. Public Health Service
Lead, Respiratory Viruses Response
U.S. Centers for Disease Control and Prevention

COVID-19 Antivirals: Closing the Treatment Gap
COVID Epi Update
Pragna Patel, MD, MPH
Chief Medical Officer
Coronavirus and Other Respiratory Viruses Division
National Center for Immunization and Respiratory Diseases 
U.S. Centers for Disease Control and Prevention

Real-World Effectiveness of COVID-19 Antivirals: The Latest Data 
Therese Tripler, PhD
Scientific Program Manager
National Center for Advancing Translational Sciences
National Institutes of Health

Clinical Considerations
Peter V. Chin-Hong, MD
Professor of Medicine and Associate Dean for Regional Campus
Director, Transplant and Immunocompromised Host Infectious Disease Program
University of California, San Francisco

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.